Journal of Clinical Oncology最新文献

{"title":"Becotatug Vedotin Combined With Pucotenlimab in Platinum- and Immunotherapy-Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma.","authors":"Dan-Yun Ruan, Feng-Hua Wang, Yujuan Zhou, Yanqun Xiang, Jinguan Lin, Lin Liu, Ping Liu, Linquan Tang, Yuxiang Ma, Tao Hou, Qiuyan Chen, Zhi-Ming Li, Fei Han, Song Qu, Sufang Qiu, Chen Han, Hongzhi Ma, Fang Su, Jin Gao, Ye Guo, Zheng Wu, Hai-Jun Wu, Yanqiu Zhao, Meiyu Fang, Man Hu, Yuan Wu, Shuo Cui, Mengyun Li, Qiong Zhao, Rui-Hua Xu","doi":"10.1200/JCO-26-00640","DOIUrl":"10.1200/JCO-26-00640","url":null,"abstract":"<p><strong>Purpose: </strong>Patients with recurrent or metastatic nasopharyngeal carcinoma (R/M NPC) have limited therapeutic options after failing platinum and anti-PD-1/PD-L1 therapy. We investigated the efficacy and safety of an epidermal growth factor receptor (EGFR)-directed antibody-drug conjugate (ADC) becotatug vedotin (BV) combined with a PD-1 inhibitor pucotenlimab in this setting of patients.</p><p><strong>Materials and methods: </strong>Magic-C001 (ClinicalTrials.gov identifier: NCT05688605) is an ongoing, open-label, multicohort, dose escalation (phase I) and expansion (phase II) study in patients with EGFR-positive solid tumors. Eligible patients received pucotenlimab 3.0 mg/kg and BV at 1.8-2.3 mg/kg (phase I) or 2.0 mg/kg (phase II for NPC) once every 3 weeks. The primary end point for phase II was objective response rate (ORR). Secondary end points included duration of response (DoR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety.</p><p><strong>Results: </strong>Among 31 patients with NPC at the recommended phase II dose (RP2D) from phase I and II who had received anti-PD-1/PD-L1 and platinum-based therapy, the confirmed ORR was 71.0% (95% CI, 52.0 to 85.8); DCR was 93.5% (95% CI, 78.6 to 99.2). The median DoR and PFS were 14.0 months (95% CI, 5.7 to not estimated) and 12.0 months (95% CI, 6.8 to 15.4), respectively. Median OS was not mature. Most common treatment-related adverse events (TRAEs) were pruritus (71.9%), hypoesthesia (65.6%), anemia (59.4%), and rash (56.3%). TRAEs of ≥grade 3 occurred in 40.6% of patients. No TRAEs led to death.</p><p><strong>Conclusion: </strong>To our knowledge, we report the first trial combining an ADC with immunotherapy for platinum and anti-PD-1/PD-L1-resistant NPC. BV plus pucotenlimab yielded a notable ORR with exceptionally durable responses and substantially prolonged PFS, alongside manageable toxicities. This regimen may offer a promising anti-PD-1 rechallenge strategy in this population, which is being confirmed in an ongoing, multicenter, randomized controlled, phase III study.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"2690-2699"},"PeriodicalIF":44.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148818648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Longitudinal Change in Cardiac Function After Doxorubicin and Dexrazoxane: A Report From Children's Oncology Group ALTE11C2.","authors":"Erin M Mobley, David R Doody, Steven D Colan, Sanjeev Aggarwal, Richard Aplenc, Saro H Armenian, K Scott Baker, Smita Bhatia, Louis S Constine, David R Freyer, Lisa M Kopp, Wendy M Leisenring, Nao Sasaki, Lynda M Vrooman, Barbara L Asselin, Cindy L Schwartz, Eric J Chow, Steven E Lipshultz","doi":"10.1200/JCO-26-00260","DOIUrl":"10.1200/JCO-26-00260","url":null,"abstract":"<p><strong>Purpose: </strong>Dexrazoxane has been associated with preservation of left ventricular (LV) systolic function in relatively small studies of long-term childhood cancer survivors. What remains less clear is whether this association is also seen in larger populations over time and what effect dexrazoxane has on cardiomyopathy screening recommendations.</p><p><strong>Methods: </strong>We analyzed echocardiographic data from participants who received doxorubicin treatment and were enrolled on Children's Oncology Group protocols P9404, P9425, P9426, P9754, and Dana Farber Cancer Institute protocol 95-01. Except for P9754, all protocols featured up-front 1:1 random assignment with dexrazoxane administered uniformly as an intravenous bolus before doxorubicin (10:1 mg/m² dexrazoxane:doxorubicin dose). Blinded central echocardiogram remeasurements were used when possible; otherwise, data were abstracted from institutional reports. Differences and associations by ± dexrazoxane were estimated using generalized estimating equations and Cox proportional hazard models, adjusting for age, sex, doxorubicin dose, chest radiotherapy, and echocardiogram data type.</p><p><strong>Results: </strong>Among 895 patients (mean follow-up, 5.9 years, 230 with ≥10-year follow-up; median doxorubicin dose, 360 mg/m²; 51% dexrazoxane-exposed) with evaluable echocardiograms (n = 2,279; 1,581 centrally remeasured; 698 report only), preserved LV systolic function was observed in patients treated with dexrazoxane (z-score difference 0.4 [95% CI, 0.2 to 0.5]) versus without. Dexrazoxane was also associated with decreased hazards of reduced LV function (fractional shortening <30% or ejection fraction <50%) occurring after 1 (0.58 [95% CI, 0.41 to 0.82]) and 5 years (0.54 [95% CI, 0.31 to 0.93]) postdiagnosis. Finally, dexrazoxane appeared to decrease the incidence of reduced LV function among those classified by current cardiomyopathy screening guidelines as high risk to rates like a lower-risk group (from 40 to 21.8 events/1,000 person-years; <i>P</i> = .001).</p><p><strong>Conclusion: </strong>Dexrazoxane exerts a significant doxorubicin cardioprotective effect on LV systolic function long term and may reduce screening needs.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"2680-2689"},"PeriodicalIF":44.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148684909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contemporary Management of Relapsed or Refractory Chronic Lymphocytic Leukemia.","authors":"Mathias Castonguay, John F Seymour","doi":"10.1200/JCO-26-00428","DOIUrl":"10.1200/JCO-26-00428","url":null,"abstract":"<p><p>Relapsed or refractory (RR) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) presents increasing therapeutic complexity in the era of targeted agents. Frontline use of covalent Bruton tyrosine kinase inhibitors (cBTKis) and venetoclax-based fixed-duration (FD) or minimal residual disease-guided regimens has led to deeper remissions, yet many patients will eventually require subsequent therapy. Management of first relapse should integrate clinical status, prior therapy, progression kinetics, and assessment for Richter transformation, along with genomic re-evaluation (particularly acquired resistance mutations and <i>TP53</i> aberrations).Multiple effective options exist for relapsing disease. Second-generation cBTKi (acalabrutinib, zanubrutinib) continuous therapy provides durable disease control with improved tolerability over ibrutinib, whereas continuous venetoclax monotherapy or FD venetoclax-rituximab achieves high response rates and prolonged remission, with retreatment feasible for selected patients. Noncovalent BTKis (ncBTKis) such as pirtobrutinib offer meaningful activity in patients previously exposed to cBTKi. Cellular therapies, particularly lisocabtagene maraleucel, have demonstrated substantial efficacy in heavily pretreated patients, and allogeneic hematopoietic cell transplantation remains an option for select individuals with double-class refractory disease. Emerging therapies-including BTK degraders, next-generation BCL2 inhibitors, and bispecific antibodies-will likely reshape the therapeutic landscape for RR CLL/SLL. With broadening treatment options for RR CLL/SLL, optimal sequencing requires consideration of disease biology, depth and duration of prior response, comorbidities, toxicity profiles, patient preferences, and logistical factors. As therapeutic options expand, individualized treatment planning and clinical trial participation remain essential for improving outcomes in RR CLL/SLL.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"2714-2724"},"PeriodicalIF":44.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148689285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Facilitated Cascade Genetic Testing for Relatives of Individuals With <i>BRCA1/2</i> Pathogenic Variants: A Randomized Controlled Trial.","authors":"Roni Nitecki Wilke, Haley A Moss, Maria D Iniesta, Xun Xu, Sarah Linhart, Ravi N Sharaf, Alexander Melamed, Karen H Lu, J Alejandro Rauh-Hain, Melissa K Frey","doi":"10.1200/JCO-26-00735","DOIUrl":"https://doi.org/10.1200/JCO-26-00735","url":null,"abstract":"<p><strong>Purpose: </strong>Despite the potential for substantial public health impact of cascade genetic testing (CGT), few at-risk relatives complete testing. We compared facilitated CGT with standard of care.</p><p><strong>Methods: </strong>Probands with newly diagnosed <i>BRCA1/2</i> germline pathogenic variants were cluster-randomized to a facilitated cascade testing intervention or standard care. Random assignment occurred at the proband level and was stratified by personal cancer history, the number of first-degree relatives (FDRs; 1-2 <i>v</i> ≥3), and time since genetic testing (≤6 months <i>v</i> >6-12 months). Adult FDRs without prior testing per self-report were enrolled. The intervention included navigation support and access to genetic testing services; control FDRs received a letter, consistent with standard clinical practice. Free germline genetic testing was available to all FDRs regardless of arm assignment. The primary outcome was completion of genetic testing at 6 months, compared using a two-sided Cochran-Mantel-Haenszel test.</p><p><strong>Results: </strong>Among 151 probands with <i>BRCA1</i> (52%) <i>or BRCA2</i> (48%) pathogenic variants, 72% had a prior cancer diagnosis. Probands were randomly assigned, with 142 and 144 FDRs assigned to the intervention and control arms, respectively. At 6 months, genetic testing uptake was significantly higher among FDRs in the intervention group compared with the control group (73.2% [adjusted 95% CI, 64.4 to 82.1] <i>v</i> 50.7% [adjusted 95% CI, 41.0 to 60.4]; <i>P</i> < .001). By 18 months, 90% of intervention FDRs completed genetic testing. Among 206 FDRs who completed testing, 95 (46%) were found to have a pathogenic or likely pathogenic variant; of these, 82 (86%) carried the familial variant.</p><p><strong>Conclusion: </strong>In this randomized trial, facilitated CGT significantly increased genetic testing uptake among FDRs of probands with <i>BRCA</i><i>1/2</i> pathogenic variants compared with standard care.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"JCO2600735"},"PeriodicalIF":44.7,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149081004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients Presenting With Locally Advanced Breast Cancer.","authors":"Andrea V Barrio, Starr Mautner, Deborah Capko, Daniel X Choi, Stephanie Downs-Canner, Marcia Edelweiss, Mahmoud El-Tamer, Gladys L Giron, Alexandra S Heerdt, Laurie J Kirstein, Minna K Lee, Cristina Lopez-Penalver, Anita Mamtani, Giacomo Montagna, Tracy-Ann Moo, George Plitas, Virgilio Sacchini, Audree B Tadros, Elizabeth Cooney, Alison C Pellecchia, Varadan Sevilimedu, Monica Morrow","doi":"10.1200/JCO-26-01114","DOIUrl":"https://doi.org/10.1200/JCO-26-01114","url":null,"abstract":"<p><strong>Purpose: </strong>To prospectively determine the false-negative rate (FNR) of sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy (NAC) in patients with locally advanced breast cancer (LABC).</p><p><strong>Methods: </strong>Patients with cT4 and/or cN2/N3 breast cancer with a nodal complete response (cN0) after NAC were eligible. SLNB was performed with dual-tracer mapping; nodal clipping was not required. All patients had a completion axillary lymph node dissection. FNR calculations were based on the patients with adequate mapping (ie, ≥3 SLNs or <3 SLNs plus clipped node). Of the planned 150 patients, we anticipated that 84 patients would have adequate mapping and that 47 would have residual disease after NAC (nodal pathologic complete response [pCR] rate: 45%). Assuming a true FNR of 10%, we estimated that this sample size would allow estimation of FNR within a margin of error (95% CI half-width) of ±8.6%.</p><p><strong>Results: </strong>From August 2017 to December 2025, 456 patients were screened for eligibility; 369 (81%) became cN0 after NAC and 145 were enrolled in the study. Of these, 44% of patients had inflammatory breast cancer (cT4d), 23% had other cT4 disease, 12% had cN2 disease, and 21% had cN3 disease. At least 1 SLN was identified in 108 patients (74%), of whom 87 had either ≥3 SLNs (n = 82) or 1-2 SLNs with a clipped node retrieved (n = 5). Of 87 patients with adequate mapping, the nodal pCR rate was 46%; of 47 (54%) with residual nodal disease, one false-negative SLN was observed, yielding an SLN FNR of 2.1% (95% CI, 0.1 to 12.7).</p><p><strong>Conclusion: </strong>In a prospective cohort of patients with LABC, the SLN identification rate was 74% and the FNR was 2.1%, suggesting that SLNB may be an appropriate method to stage the axilla in LABC after downstaging with NAC.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"JCO2601114"},"PeriodicalIF":44.7,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149081022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: Omitting Bone Marrow Sampling in FDG-Avid Rhabdomyosarcoma With 2-[18F]FDG PET-Negative Marrow: Results From an International Retrospective Study.","authors":"Federico Mercolini, Marissa Just, Barry L Shulkin, Natalie B Collins, Jacquelyn Crane, Douglas Harrison, Maria C Affinita, Wendy Allen-Rhoades, Alessandra Alessi, Sebastian D Asaftei, Michael A Arnold, Sonja Chen, Stefano Chiaravalli, Forrest FitzGerald, Martin T Freitag, Jessica L Iftner, Hedieh Khalatbari, Bart de Keizer, Irene von Luettichau, Christine Mauz-Körholz, Claudia Rossig, Guido Rovera, Stefan Rutkowski, Justin B Sims, Stephan D Voss, Ayami Yoshimi, Suzi Birz, Gianni Bisogno, Martin Ebinger, Johannes H M Merks, Monika Sparber-Sauer, Bernhard Haller, Aaron R Weiss, Corinne M Linardic, Reineke A Schoot, Simone Hettmer","doi":"10.1200/JCO-26-02359","DOIUrl":"10.1200/JCO-26-02359","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"JCO2602359"},"PeriodicalIF":44.7,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149074598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surgery and tile-based radiation therapy versus surgery and stereotactic radiation for newly diagnosed brain metastases (ROADS): a randomized, open-label, phase 3 trial.","authors":"Jeffrey S Weinberg, Brandon S Imber, Vincent DiNapoli, Nelson S Moss, Kimberly B Hoang, Fen Wang, Imran Mohiuddin, Akshitkumar M Mistry, Michael A Garcia, Hussein Tawbi, Nitesh V Patel, Huong Pham, Robert Ryan, John Wanebo, Kris Smith, Clark C Chen, Alexandra Paul, Lindsey Sloan, Matthew J Shepard, Ken Tatebe, Colette J Shen, David G Brachman, Angela M Richardson, Linton T Evans, Gregory B Biedermann, Adam Robin, Toral R Patel, Aristotelis Filippidis, Heather Lin, Lola B Chambless, John Dombrowski, Akash J Patel, Sajeel Chowdhary, K Stuart Lee, M Sean Peach, Adam Nowlan, David J McCracken, John Floyd, Fen Xia, Jeremy Rudnick, Jing Li, Debra Nana Yeboa, Frederick F Lang, Rajat J Kudchadker, Mary Frances McAleer, Jeffrey Wefel, Sherise Desiree Ferguson, Ying Yuan, Simon Hanft, Thomas H Beckham","doi":"10.1200/JCO-26-01894","DOIUrl":"https://doi.org/10.1200/JCO-26-01894","url":null,"abstract":"<p><strong>Purpose: </strong>Post-operative stereotactic radiation (SRT) is the standard-of-care for resected brain metastases. Implantation of cesium-131 collagen tiles (tile-based radiation therapy, TBRT) initiates focal radiation immediately after resection, potentially offering therapeutic and logistical advantages. ROADS: a randomized, open-label, non-inferiority, phase 3 trial (NCT04365374) compared the safety and efficacy of resection with TBRT (R+TBRT) to resection with SRT (R+SRT) for patients with a newly diagnosed brain metastasis indicated for surgical resection.</p><p><strong>Patients and methods: </strong>Across 32 United States centers, patients were pre-operatively randomized 1:1 to resection R+TBRT or R+SRT. Any non-resected brain metastases received SRT post-operatively. Co-primary outcomes were time-to-surgical bed recurrence (SBR) and surgical bed recurrence-free survival (SB-RFS). Outcomes were analyzed using Cox proportional hazards models with stratification factors as covariates. Multiplicity was controlled by hierarchical testing. Analyses used the pre-specified modified intent-to-treat (mITT) population (patients who underwent surgery, had pathologic confirmation of brain metastasis, and had follow-up information).</p><p><strong>Results: </strong>From April 2021 through August 2025, 230 patients were randomized (115 per arm); 204 of whom (103 R+TBRT, 101 R+SRT) comprised the mITT population. Median follow-up was 12.9 months. Median time-to-SBR was not reached (R+TBRT) versus 17.4 months (R+SRT) (hazard ratio [HR]: 0.06; 95% confidence interval [CI]: 0.01-0.46; p=0.0070). SB-RFS was improved with R+TBRT, with a median of not reached versus 10.9 months (R+SRT) (HR: 0.48; 95% CI: 0.30-0.76; p=0.0021). Overall adverse events did not appear to differ: 83 patients (79.0%, 95% CI: 70.0-86.4) (R+TBRT) versus 67 patients (80.7%, 95% CI:70.6-88.6) (R+SRT).</p><p><strong>Conclusion: </strong>For patients with newly diagnosed brain metastases requiring resection, R+TBRT significantly improved SBR and SB-RFS, demonstrating both non-inferiority and superiority.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"101200JCO2601894"},"PeriodicalIF":44.7,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149074615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Transplant-Ineligible Subgroup Analysis of CEPHEUS","authors":"Saad Z. Usmani, Thierry Facon, Vania Hungria, Nizar J. Bahlis, Christopher P. Venner, Marc Braunstein, Ludek Pour, Josep M. Marti, Supratik Basu, Yael C. Cohen, Morio Matsumoto, Kenshi Suzuki, Cyrille Hulin, Sebastian Grosicki, Wojciech Legiec, Meral Beksac, Angelo Maiolino, Hiroyuki Takamatsu, Aurore Perrot, Mehmet Turgut, Weiping Liu, Jianping Wang, Maria Krevvata, Jaclyn Stanziola, Matteo Loi, Emilie M.J. Van Brummelen, Lorena Lopez-Masi, Melissa Rowe, Robin L. Carson, Sonja Zweegman","doi":"10.1200/jco-26-00401","DOIUrl":"https://doi.org/10.1200/jco-26-00401","url":null,"abstract":"Journal of Clinical Oncology, Ahead of Print. <br/>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"30 1","pages":""},"PeriodicalIF":45.3,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149049024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biases in the Interpretation of TRANSFORM Circulating Tumor DNA Data: Assessment Timing, Event Definition, and Subset Selection","authors":"Li-Xuan Qin","doi":"10.1200/jco-26-01257","DOIUrl":"https://doi.org/10.1200/jco-26-01257","url":null,"abstract":"Journal of Clinical Oncology, Ahead of Print. <br/>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"30 4 1","pages":""},"PeriodicalIF":45.3,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149049026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to: Biases in the Interpretation of TRANSFORM Circulating Tumor DNA Data: Assessment Timing, Event Definition, and Subset Selection","authors":"Lara Stepan, Sahar Ansari, Jeremy S. Abramson","doi":"10.1200/jco-26-02069","DOIUrl":"https://doi.org/10.1200/jco-26-02069","url":null,"abstract":"Journal of Clinical Oncology, Ahead of Print. <br/>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"52 1","pages":""},"PeriodicalIF":45.3,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149049022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}